摘要
Abstract
Objective To study the relationship between serum miR‐574‐5p expression and clinical pathological characteristics in patients with breast cancer .Methods Totally 60 patients with breast cancer and 60 patients with fibroadenoma of breast were se‐lected as the research subjects from December 2014 to September 2015 ,and 60 cases of healthy women in the hospital were selected as control group .The real‐time fluorescence quantitative PCR(qPCR) was used to test serum miR‐574‐5p level .Results By RT‐PCR detection ,serum miR‐574‐5p level of breast cancer was 55 .26 ± 6 .71 ,serum levels miR‐574‐5p of fibroids group was 14 .21 ± 4 .11 ,and level of miR‐574‐5p of healthy controls serum was 3 .39 ± 1 .02 .MiR‐574‐5p level of patients with breast cancer was high‐er than that of the fibroadenoma group and control group ,and differences were statistically significant(F=68 .17 ,P<0 .05) ,and miR‐574‐5p levels of fibroadenoma were higher than that of the healthy control group ,and difference was statistically significant (t=21 .08 ,P<0 .05) .With the increase of pathological staging ,the increase of tumor volume and decrease of degree of differentia‐tion ,serum miR‐574‐5p levels of breast cancer were increased .Serum miR‐574‐5p level of patients with breast cancer combined with lymph node metastasis was significantly higher than that of the patients without lymph node metastasis(P<0 .05) .After surgery , serum miR‐574‐5p level of patients with the breast cancer (46 .19 ± 6 .15) was lower than before (54 .91 ± 6 .62) ,and the difference was statistically significant(t=16 .72 ,P<0 .05) .Conclusion Serum miR‐574‐5p level of breast cancer is higher than that of benign breast lesions and healthy people .Serum miR‐574‐5p level is closely related to the pathological characteristics and prognosis of breast cancer .Breast cancer radical operation can inhibit the expression of miR‐574‐5p and improve the patients′disease condition .关键词
乳腺癌/miR-574-5p/病理特征/乳腺癌改良根治术/表达水平Key words
breast cancer/miR-574-5p/pathological characteristics/breast cancer modified radical/expression level
